PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc

Neuroblastoma (NB) is one of the most common solid tumors in childhood. To date, targeting MYCN, a well-established driver gene in high-risk neuroblastoma, is still challenging. In recent years, inhibition of bromodomain and extra terminal (BET) proteins shows great potential in multiple of Myc-driven tumors. ARV-825 is a novel BET inhibitor using proteolysis-targeting chimera (PROTAC) technology which degrades target proteins by the proteasome. In this study, we investigated the effect of ARV-825 in neuroblastoma in vitro and in vivo. Our results showed that ARV-825 treatment robustly induced proliferative suppression, cell cycle arrest, and apoptosis in NB cells. Moreover, ARV-825 efficiently depleted BET protein expression, subsequently repressing the expression of MYCN or c-Myc. In the NB xenograft model, ARV-825 profoundly reduced tumor growth and led to the downregulation of BRD4 and MYCN expression in mice. Taken together, these findings provide evidence that PROTAC BET inhibitor is an efficient way to achieve MYCN/c-Myc manipulation, and ARV-825 can be used as a potential therapeutic strategy for the treatment of neuroblastoma.

[1]  Yongcheng Song,et al.  Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy , 2020, Journal of Hematology & Oncology.

[2]  C. Crews,et al.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery , 2020, Cell.

[3]  Xiaojuan Du,et al.  The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells , 2019, Journal of Cancer.

[4]  Shuijun Zhang,et al.  Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells , 2020, Frontiers in Oncology.

[5]  Melinda M. Mulvihill,et al.  Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity , 2020, ChemMedChem.

[6]  J. Qi,et al.  BET bromodomain inhibition suppresses adipogenesis in mice , 2019, Endocrine.

[7]  R. Davis,et al.  BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. , 2019, The Journal of clinical investigation.

[8]  Shaomeng Wang,et al.  Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. , 2019, Drug discovery today. Technologies.

[9]  T. Tan,et al.  Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma , 2019, Nature Communications.

[10]  J. Tyner,et al.  Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations , 2019, Haematologica.

[11]  Nilay Shah,et al.  Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma1 , 2018, bioRxiv.

[12]  Huiting Zhou,et al.  A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction , 2018, The American journal of surgical pathology.

[13]  Liu Liu,et al.  Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. , 2018, Journal of Medicinal Chemistry.

[14]  R. Young,et al.  Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry , 2018, Nature Genetics.

[15]  Ling-Zhi Wang,et al.  Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma , 2018, Proceedings of the National Academy of Sciences.

[16]  Nilay Shah,et al.  Dual BRD4 and AURKA Inhibition is Synergistic against MYCN-amplified and nonamplified Neuroblastoma , 2018, bioRxiv.

[17]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[18]  V. Baladandayuthapani,et al.  Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma , 2018, Leukemia.

[19]  D. Rickman,et al.  The Expanding World of N-MYC-Driven Tumors. , 2018, Cancer discovery.

[20]  J. Lehtiö,et al.  MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling , 2018, Proceedings of the National Academy of Sciences.

[21]  A. Stathis,et al.  BET Proteins as Targets for Anticancer Treatment. , 2018, Cancer discovery.

[22]  Richard A. Young,et al.  MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. , 2018, Cancer discovery.

[23]  Guang-Hui Qian,et al.  Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4 , 2017, Oncology reports.

[24]  D. Lamont,et al.  Structural basis of PROTAC cooperative recognition for selective protein degradation , 2017, Nature chemical biology.

[25]  P. Qiu,et al.  Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells , 2016, Leukemia.

[26]  M. D’Incalci,et al.  The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus , 2016, Oncotarget.

[27]  M. Esteller,et al.  Bromodomain inhibitors and cancer therapy: From structures to applications , 2016, Epigenetics.

[28]  F. Grosso,et al.  Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts , 2017, International journal of cancer.

[29]  Tomomi Noguchi-Yachide.  BET Bromodomain as a Target of Epigenetic Therapy. , 2016, Chemical & pharmaceutical bulletin.

[30]  G. Pelosi,et al.  Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. , 2016, Cancer discovery.

[31]  G. Salles,et al.  Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. , 2016, The Lancet. Haematology.

[32]  J. Bradner,et al.  The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects , 2016, Clinical Cancer Research.

[33]  F. Westermann,et al.  Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition , 2015, Clinical Cancer Research.

[34]  D. Chung,et al.  Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. , 2015, Surgery.

[35]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[36]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[37]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[38]  A. Ciulli,et al.  Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.

[39]  H. Dombret,et al.  BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells , 2015, Oncotarget.

[40]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[41]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[42]  William A Weiss,et al.  Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.

[43]  Travis J Cohoon,et al.  Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[44]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[45]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[46]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[47]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[48]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[49]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[50]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[51]  Rainer König,et al.  Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.

[52]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.